The FDA grants CD33-specific CAR+ T cell Investigational New Drug Application clearance for treatment of R/R AML – AML Global Portal
|
The FDA grants CD33-specific CAR+ T cell Investigational New Drug Application clearance for treatment of R/R AML
AML Global Portal On 2nd May 2017, the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application and granted clearance for CD33-specific Chimeric Antigen Receptor (CAR) + T–cell therapy for patients with Relapsed or Refractory … |
